Research
Hormonal
The combination of canagliflozin and metformin in a single tablet may improve medication adherence in type 2 diabetes.
Using a fixed-dose combination may enhance patient compliance with diabetes treatment regimens.
StrongSupportsmedium confidence
The combination in a single tablet given once daily should help to simplify therapy and improve medication adherence in T2D.
Why this rating
The claim is based on a review of literature regarding the combination therapy.
Source
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
Brian Tomlinson et al. · Expert Opinion on Pharmacotherapy · 2023
DOI 10.1080/14656566.2023.2276180
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →